X
1. (2s)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile
2. Galvus
3. Nvp Laf237
4. Nvp-laf237
5. Vildagliptin
1. Vildagliptin
2. 274901-16-5
3. (2s)-1-((3-hydroxyadamantan-1-yl)glycyl)pyrrolidine-2-carbonitrile
4. (2s)-1-[2-[[(5s,7r)-3-hydroxy-1-adamantyl]amino]acetyl]pyrrolidine-2-carbonitrile
5. 1044676-63-2
6. Chembl319819
7. Chembl3084811
8. Schembl10031674
9. Schembl16153676
10. Schembl16155482
11. (s)-1-(2-(((1r,3r,5r,7s)-3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile
12. Laf237;nvp-laf 237
13. Bdbm123776
14. Zinc3976077
15. Bdbm50129889
16. Fd6071
17. Mfcd08275142
18. Akos015924571
19. Zinc100013465
20. Zinc100492199
21. Bs-1016
22. 901v165
23. Q-101364
24. Q27462467
25. 1-[2-(3-hydroxy-adamantan-1-ylamino)-acetyl]-pyrrolidine-2-carbonitrile
26. (s)-1-(((1r,3r,5r,7s)-3-hydroxyadamantan-1-yl)glycyl)pyrrolidine-2-carbonitrile
27. (2s)-1-(2-{[(1r,3s,5r,7s)-3-hydroxyadamantan-1- Yl]amino}acetyl)pyrrolidine-2-carbonitrile (11)
28. (2s)-1-{n-[(1r,3s,5r,7s)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]glycyl}pyrrolidine-2-carbonitrile
| Molecular Weight | 303.4 g/mol |
|---|---|
| Molecular Formula | C17H25N3O2 |
| XLogP3 | 0.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Exact Mass | 303.19467705 g/mol |
| Monoisotopic Mass | 303.19467705 g/mol |
| Topological Polar Surface Area | 76.4 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 523 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:
as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:
- as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.
- in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 and 5. 1 for available data on different combinations).
Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:
- as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.
- in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 and 5. 1 for available data on different combinations).
Treatment of type II diabetes mellitus
Dipeptidyl-Peptidase IV Inhibitors
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release. (See all compounds classified as Dipeptidyl-Peptidase IV Inhibitors.)
Hypoglycemic Agents
Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)
A10BH02
A10BH02
A10BH02
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10B - Blood glucose lowering drugs, excl. insulins
A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors
A10BH02 - Vildagliptin
Market Place
